Target intelligence / Profile preview

MicroRNA 5739 (miR-5739)

Target
miR-5739
Molecular classification
MicroRNA (miRNA), Non-coding RNA
01

Overview

MicroRNA 5739 (miR-5739) is a human microRNA (non-coding RNA) that plays an essential role in embryonic mesoderm development, specifically controlling the proliferation, differentiation, and maturation of muscle and vascular cell lineages through post-transcriptional gene silencing. It acts by binding the 3′ untranslated regions of target mRNAs to suppress their expression, directly regulating key genes such as SMA, Brachyury T, Hand1 (in muscle lineage), and KDR and Endoglin (in vascular lineage). Experimental knockout of miR-5739 in human embryonic stem cells leads to profound defects in muscle and blood vessel formation, while its expression is markedly decreased in pathological tissues from patients with both congenital muscle and vascular diseases. These functions highlight miR-5739 as a promising candidate for cell therapy research in genetic diseases and as a novel biomarker for diagnosis and monitoring of muscle/vascular pathologies.

Other names
hsa-mir-5739microRNA mir-5739MIR5739
02

Mechanism of action

Binds to target gene 3′ untranslated regions to suppress expression via RNA interference (canonical miRNA action). Targets specific genes for muscle (SMA, Brachyury T, Hand1) and vascular (KDR, Endoglin) differentiation.

03

Biological functions

Regulation of gene expression through post-transcriptional silencingMesoderm development, especially muscle and vascular cell differentiationRegulation of angiogenesis and morphogenesis
04

Disease associations

Muscular dystrophy (decreased expression in Duchenne muscular dystrophy patient-derived cells)Hereditary hemorrhagic telangiectasia (vascular abnormality, decreased expression found in patient cells)
05

Safety considerations

Knockout models exhibit impaired muscle and vascular differentiation, suggesting potential developmental risks if miR-5739 is suppressed in embryonic or regenerative contextsClinical application would need careful monitoring to avoid unintended lineage development deficits
06

Biomarkers

Expression level of miR-5739 as potential biomarker for congenital muscle diseases (e.g., Duchenne muscular dystrophy) and vascular abnormalities (e.g., hereditary hemorrhagic telangiectasia)

Beyond the preview

Go deeper on MicroRNA 5739 (miR-5739).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroRNA 5739 (miR-5739).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call